Partner Headlines - GSK

  1. Stock Futures Up, But Wobbly; Boeing, Apple, Biogen Rising

    IBD
  2. Mylan Wins Motion To Enjoin GlaxoSmithKline From Providing Paroxetine ...

    Benzinga
  3. Morning Market Movers

    Benzinga
  4. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With ...

    Benzinga
  5. Highest Yielding Stocks Widely Held By The Gurus

    GuruFocus
  6. British Stocks: Sweet Spot For European Value

    YCharts
  7. Diamond Hill Capital Comments on GlaxoSmithKline PLC

    GuruFocus
  8. ISIS Pharma Trades Up Premarket; NYT Says Has Potential Heart ...

    Benzinga
  9. Advances In HIV, Hep C Treatments Could Spark Renewed Interest ...

    Benzinga
  10. InterMune Up On Bullish View Of U.S. Esbriet Launch

    IBD
  11. UPDATE: Glaxo, Theravance Report Positive Data from Two Studies ...

    Benzinga
  12. Major British Companies Lead Top Guru-Held UK and Ireland Stocks ...

    GuruFocus
  13. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  14. ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica ...

    Benzinga
  15. Aura Of Light Shines On Pernix Shares Following Treximet Acquisition

    Benzinga
  16. Cross-Border Megamergers Drive Global Takeover Boom

    IBD
  17. Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry

    Benzinga
  18. Can Pfizer Make Up Its Loss?

    GuruFocus
  19. Merck Sells Consumer Unit To Bayer To Focus On R&D

    IBD
  20. Bayer Buys Merck Consumer Care Unit

    FoxBusiness
  21. AstraZeneca Rejects Pfizer's $106B Buyout Bid

    FoxBusiness
  22. #PreMarket Primer: Thursday, May 1: Fed Brushes Off Dissapointing ...

    Benzinga
  23. Glaxo hurt by Advair scandal

    IBD
  24. Nasdaq Leads Early Stock Slide; Twitter Tumbles, Trinity Rises

    IBD
  25. Stock Futures Slip as Traders Brace for Economic Flood

    FoxBusiness
  26. Disappointing GDP Reading Weighs on Stocks

    FoxBusiness
  27. China Rule Change Further Opens Yuan To World Markets

    IBD
  28. Weekly 52-Week Highs Highlight: AV, XEL, OKE, GSK

    GuruFocus
  29. GSK, MMV Announce Commencement of Phase III Programme of Tafenoquine ...

    Benzinga
  30. These Three Pharmaceutical Companies Shake The Market With Their ...

    GuruFocus
  31. Benzinga Weekly Preview: Earnings Season Continues As Biotech ...

    Benzinga
  32. Big Pharmas Swap Specialties

    IBD
  33. Drugmakers Prod European Stocks To Post-Easter Rally

    IBD
  34. Valeant's Bid For Allergan Boosts Ethical Drug Stocks

    IBD
  35. Novartis, Glaxo Swap Units; Valeant Bids For Allergan

    IBD
  36. Stocks Rise In Higher Volume; Gilead Up After Hours

    IBD
  37. S&P 500, Nasdaq Rise For Sixth Day As Volume Picks Up

    IBD
  38. Pharma Deal Frenzy: A Bid to Boost Profits, Cut Risk

    FoxBusiness
  39. Amgen Slumps After 1Q Earnings Miss

    FoxBusiness
  40. Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)

    Benzinga
  41. Novartis, Glaxo Swap Units; Lilly Buying Animal Biz

    IBD
  42. Stock Futures Mixed And Busy; Allergan, Netflix, Glaxo Climb

    IBD
  43. Novartis Announces Multi-Billion-Dollar Revamp

    FoxBusiness
  44. US Stock Futures Edge Higher Ahead Of McDonald's Earnings

    Benzinga
  45. Stock Futures Steady Amid Raft of Health M&A

    FoxBusiness
  46. Wall Street Ticks Up as Traders Parse News Deluge

    FoxBusiness
  47. GlaxoSmithKline Finally Received Approval from FDA for Its Diabetes ...

    GuruFocus
  48. Has A Streamlined FDA Raised The Value Of Drug Stocks?

    IBD
  49. Pharmaceutical Stocks For Income, Value, And Growth Investors

    Benzinga
  50. New Glaxo bribery inquiries

    IBD
  51. Race for Vaccines, Treatments as West Africa Ebola Death Toll ...

    Benzinga
  52. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With ...

    Benzinga
  53. GlaxoSmithKline

    IBD
  54. Amgen, GSK End Marketing Pact for Osteoporosis Drug

    FoxBusiness
  55. Biotech Auxilium Boosts Position In Men's Health Care

    IBD
  56. Glaxosmithkline Confirms Warning Letter Received from FDA o March ...

    Benzinga
  57. GSK buys up Indonesia unit

    IBD
  58. GSK Recalls Alli in U.S. After Package Tampering

    FoxBusiness
  59. GSK, FDA Probe Tampering of Weight-Loss Drug Alli

    FoxBusiness
  60. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  61. Market Wrap For March 20: Investors Showing No Post-Fed Decision ...

    Benzinga
  62. Glaxo Cancer Vaccine Fails, Testing Continues

    FoxBusiness
  63. Morning Market Losers

    Benzinga
  64. US Stock Futures Drop Ahead Of Jobless Claims Report

    Benzinga
  65. Agenus Therapeutics Reports GlaxoSmithKline's Magrit Study Does ...

    Benzinga
  66. T. Rowe Price's Brian Rogers Joins GuruFocus for Q&A - Ask an ...

    GuruFocus
  67. T. Rowe Price CIO Brian Rogers Joins GuruFocus for Q&A - Ask ...

    GuruFocus
  68. Gilead's HCV Challengers Near The Starting Gate

    IBD
  69. Brian Rogers of T. Rowe Price Joins GuruFocus for Q&A - Ask a ...

    GuruFocus
  70. Gilead's HCV Challengers Near The Starting Gate

    IBD
  71. Prosensa Muscular Dystrophy Data Send Stock Rising

    IBD
  72. A HIV shot could replace pills

    IBD
  73. Why Long-Term Investor Warren Buffett's Company Just Sold 2 Stocks

    GuruFocus
  74. GlaxoSmithKline, Kinder Morgan And Others Insiders Have Been ...

    Benzinga
  75. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness
  76. Berkshire Hathaway Files SEC 13F

    Benzinga
  77. Pharmacyclics' Imbruvica Wins Second Cancer Approval

    IBD
  78. Novartis' 'Cliffy' Business

    GuruFocus
  79. Glaxo expects to retain lead

    IBD
  80. Benzinga Weekly Preview: Twitter To Release Earnings For The ...

    Benzinga
  81. Ariad Shares Continue to Surge Amidst Buyout Rumors

    Benzinga
  82. Tweedy Browne Global Value Fund New Buy and Adds

    GuruFocus
  83. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts
  84. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts
  85. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  86. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think ...

    GuruFocus
  87. Morning Market Losers

    Benzinga
  88. Benzinga's Top #PreMarket Losers

    Benzinga
  89. Pharmacyclics, Valeant, Celgene Up On Bullish News

    IBD
  90. PharmacyclicsDrug Trial To End Early On Strong Data

    IBD
  91. Stock Futures Positive, Steady; Netflix Dives On Downgrade

    IBD
  92. New Drugs Could Change Cancer Landscape In 2014

    IBD
  93. ObamaCare = Drug Maker Assistance Act

    YCharts
  94. Why MasterCard, Up 64% in 2013, Isn’t Done

    YCharts
  95. Merck’s Bad-Mouthing Of Generic: $21 Million Fine

    YCharts
  96. Prosensa Comments on Drisapersen Program Update

    Benzinga
  97. Merck Collaborates with GlaxoSmithKline on MK-3475

    Benzinga
  98. Glaxo Curbs Drug Promotion

    IBD
  99. Pharma’s Pay-to-Delay Deals Targeted Again

    YCharts
  100. Pfizer’s Great Hope Xeljanz: More Bad News

    YCharts
Trading Center